Sanjib Basu

Sanjib Basu

Auto-generated profile, based on publicly available information

Sanjib Basu

Division of Epidemiology and Biostatistics, University of Illinois Chicago , 1603 W. Taylor St, Chicago, IL 60612

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BDBenjamin A Derman
Benjamin A Derman
JMJ. N. Macklis
J. N. Macklis
MAM. S. Azeem
M. S. Azeem
SSS. Sayidine
S. Sayidine
SBS. Basu
S. Basu
MFMary Fidler
Mary Fidler
There is emerging evidence showing a significant relationship between overall survival (OS) in non-small cell lung cancer NSCLC patients and weight change during chemotherapy or chemoradiation. A high neutrophil/lymphocyte ratio (NLR) at baseline and at follow-up is associated with shorter survival in cancer patients and may be a surrogate for ongoing inflammation, implicated in cancer cachexia and tumor progression. The objective of this study is to explore potential relationships between OS, serial weights, and serial NLRs in advanced NSCLC patients receiving chemotherapy. One hundred thirty-nine patients with chemotherapy-naïve NSCLC, predominantly with stage III/IV disease, were treated with first-line platinum doublets from June, 2011 to August, 2012. NLR, tumor response, and body weight were recorded at baseline, 6, and 12 weeks from initiation of therapy and correlated with OS. The association between NLR and OS was assessed using Cox PH (proportional hazards) analysis, the association between NLR and weight change was assessed using a simple regression analysis, and the association between NLR and tumor response was assessed using the Fisher’s exact test. One hundred thirty-nine patients with median age 68, PS 0-1/2 = 83/17%, male/female = 58%/42%. Median NLR at baseline was 3.6 (range 0.1898 to 30.910), at 6 weeks 3.11 (range 0.2703 to 42.11), and at 12 weeks 3.52 (range 0.2147 to 42.93). A Higher NLR at baseline, 6, and 12 weeks was associated with decreased OS (baseline: HR 1.06, p < 0.001; 6 weeks: HR 1.07, p = 0.001; 12 weeks: HR 1.05, p < 0.001), and longitudinal NLR, as a time-dependent covariate, was also associated with decreased OS (HR = 1.06, p < 0.001). Baseline weight and NLR were inversely related (cor = −0.267, p = 0.001), and weight change and NLR were inversely related at 12 weeks (cor = −0.371, p < 0.001). Longitudinal measurements of weight and NLR were also negatively associated (slope = −0.06, p < 0.001). Using a cutoff of NLR > 5, there was a significant association between progressive disease and NLR > 5 at 6 weeks (p = 0.02) and 12 weeks (p = 0.03). High baseline and progressive increases in NLRs are associated with progressive disease, inferior OS and weight loss in NSCLC patients. In addition to having prognostic significance, these observations suggest that studying molecular mediators of cachexia/inflammation and their relationships to tumor progression may identify new therapeutic targets in the large subset of NSCLC patients who have cancer cachexia.

20 March 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MFMary Fidler
Mary Fidler
CFCristina L. Fhied
Cristina L. Fhied
JGJulia Grigorieva
Julia Grigorieva
SBSanjib Basu
Sanjib Basu
SSSelina Sayidine
Selina Sayidine
Jeffrey A. BorgiaJeffrey A. Borgia
Jeffrey A. Borgia
The VeriStrat test is a serum proteomic signature originally discovered in non-responders to second line gefitinib treatment and subsequently used to predict differential benefit from erlotinib versus chemotherapy in previously treated advanced non-small cell lung cancer (NSCLC). Multiple studies highlight the clinical utility of the VeriStrat test, however, the mechanistic connection between VeriStrat-poor classification and poor prognosis in untreated and previously treated patients is still an active area of research. The aim of this study was to correlate VeriStrat status with other circulating biomarkers in advanced NSCLC patients – each with respect to clinical outcomes. Serum samples were prospectively collected from 57 patients receiving salvage chemotherapy and 70 non-EGFR mutated patients receiving erlotinib. Patients were classified as either VeriStrat good or poor based on the VeriStrat test. Luminex immunoassays were used to measure circulating levels of 102 distinct biomarkers implicated in tumor aggressiveness and treatment resistance. A Cox PH model was used to evaluate associations between biomarker levels and clinical outcome, whereas the association of VeriStrat classifications with biomarker levels was assessed via the Mann-Whitney Rank Sum test. VeriStrat was prognostic for outcome within the erlotinib treated patients (HR = 0.29, p < 0.0001) and predictive of differential treatment benefit between erlotinib and chemotherapy ((interaction HR = 0.25; interaction p = 0.0035). A total of 27 biomarkers out of 102 unique analytes were found to be significantly associated with OS (Cox PH p ≤ 0.05), whereas 16 biomarkers were found to be associated with PFS. Thrombospondin-2, C-reactive protein, TNF-receptor I, and placental growth factor were the analytes most highly associated with OS, all with Cox PH p-values ≤0.0001. VeriStrat status was found to be significantly associated with 23 circulating biomarkers (Mann-Whitney Rank Sum p ≤ 0.05), 6 of which had p < 0.001, including C-reactive protein, IL-6, serum amyloid A, CYFRA 21.1, IGF-II, osteopontin, and ferritin. Strong associations were observed between survival and VeriStrat classifications as well as select circulating biomarkers associated with fibrosis, inflammation, and acute phase reactants as part of this study. The associations between these biomarkers and VeriStrat classification might have therapeutic implications for poor prognosis NSCLC patients, particularly with new immunotherapeutic treatment options.

2 June 2022 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
SASarah Allam
Sarah Allam
EPElizabeth Ann Paris
Elizabeth Ann Paris
ILItzel Lazcano
Itzel Lazcano
PBPincas Bitterman
Pincas Bitterman
SBSanjib Basu
Sanjib Basu
ABAnimesh Barua
Animesh Barua
Emerging information suggests a potential role of medicinal cannabis in pain medication in addition to enhancing immune functions. Endometriosis is a disease of women of reproductive age associated with infertility and reproductive failure as well as chronic pain of varying degrees depending on the stage of the disease. Currently, opioids are being preferred over nonsteroidal anti-inflammatory drugs (NSAID) due to the latter’s side effects. However, as the opioids are becoming a source of addiction, additional pain medication is urgently needed. Cannabis offers an alternative therapy for treating the pain associated with endometriosis. Information on the use and effectiveness of cannabis against endometriotic pain is lacking. Moreover, expression of receptors for endocannabinoids by the ovarian endometriotic lesions is not known. The goal of this study was to examine whether cannabinoid receptors 1 and 2 (CB1 and CB2) are expressed by ovarian endometriotic lesions. Archived normal ovarian tissues, ovaries with endometriotic lesions, and normal endometrial tissues were examined for the presence of endometrial stromal cells using CD10 (a marker of endometrial stromal cells). Expression of CB1 and CB2 were determined by immunohistochemistry, immunoblotting, and gene expression studies. Intense expression for CB1 and CB2 was detected in the epithelial cells in ovarian endometriotic lesions. Compared with stroma in ovaries with endometriotic lesions, the expression of CB1 and CB2 was significantly higher in the epithelial cells in endometriotic lesions in the ovary ( and , respectively). Immunoblotting and gene expression assays showed similar patterns for CB1 and CB2 protein and CNR1 (gene encoding CB1) and CNR2 (gene encoding CB2) gene expression. These results suggest that ovarian endometriotic lesions express CB1 and CB2 receptors, and these lesions may respond to cannabinoids as pain medication. These results will form a foundation for a clinical study with larger cohorts.

1 May 2003 in Technometrics
Verified
Journal Article
Closed access
SBSanjib Basu
Sanjib Basu
NENader Ebrahimi
Nader Ebrahimi
This article proposes new Bayesian models for software reliability based on a piecewise constant failure rate. A martingale process prior is assumed on the failure rate. Three different hyperprior models on the martingale process are considered. The first two models assume that the conditional variance is dependent on the mean, whereas the third model assumes constant conditional variance. Markov chain sampling–based posterior analysis and prequential predictions are developed for these models and are illustrated in a software failure dataset. In addition, model comparison is studied via the Bayes factor criterion. General techniques are described for estimating the marginal likelihood of the proposed models as well as of many existing software reliability models, and these are illustrated in two datasets.

27 April 2021 in Journal of the Royal Statistical Society Series C: Applied Statistics
Verified
Journal Article
Closed access
PDF file
AMArnab Kumar Maity
Arnab Kumar Maity
SBSanjib Basu
Sanjib Basu
SGSantu Ghosh
Santu Ghosh

8 May 2014 in Arthroscopy
Verified
Journal Article
Closed access
BLBrett A. Lenart
Brett A. Lenart
RFRyan Freedman
Ryan Freedman
GTGeoffrey S. Van Thiel
Geoffrey S. Van Thiel
ADAman Dhawan
Aman Dhawan
KMKevin C. McGill
Kevin C. McGill
NVNikhil N. Verma
Nikhil N. Verma